EMERSON, N.J.--(BUSINESS WIRE)--Energex Systems, Inc. announced today that its experimental therapy known as HemoModulation was effective in reducing viral load and liver inflammation in non-responding Hepatitis C patients. The trial was conducted under an Investigational Device Exemption (IDE) that was granted by the Federal Food and Drug Administration (FDA) in February 2006.
